Supervised Injection Services: Evidence and Practice

Similar documents
HARM REDUCTION IN CANADA LESSONS LEARNED AND REFLECTIONS. Marilou Gagnon, RN, PhD Associate Professor School of Nursing University of Victoria

STAFF REPORT ACTION REQUIRED. Supervised Injection Services in Toronto SUMMARY. Date: June 21, Board of Health. To: Medical Officer of Health

Ontario Harm Reduction Conference April 30 to May 2, 2017 Toronto, Ontario

15 Years of Supervised Drug Consumption Vancouver, Canada

Observational Substance Use Epidemiology: A case study

Questions & Answers. What are the risks associated with consumption drug use?

Drug Consumption Rooms Worldwide

Ontario Harm Reduction Conference April 30 to May 2, 2017 Toronto, Ontario

Becoming a harm reduction distribution agency in Toronto - information session

Strategies to Reduce Harm and HIV/AIDS Infection among Drug Using Populations

Supervised Consumption Facilities Review of the Evidence SHARON LARSON, PHD NORMA PADRON, PHD JENNIFER MASON TYLER BOGACZYK

Vancouver s Pilot Medically Supervised Safer Injecting Facility Insite

Harm Reduction in the Hospital: Preventing AMA Discharges and ED Bounce Backs

SAN FRANCISCO SAFE INJECTION SERVICES TASK FORCE

Frequently Asked Questions about Supervised Injecting Facilities 24 July 2014

Public Health Association of British Columbia

Supervised Consumption: A Report to the Community of Medicine Hat

ETHNO-EPIDEMIOLOGICAL APPROACHES TO UNDERSTANDING DRUG-RELATED RELATED HARM

Participant views and experiences of participating in HIV research in sub-saharan Africa: a qualitative systematic review protocol

Changes in injecting practices associated with the use of a medically supervised safer injection facility

Chad Sabora, BS, MS, JD Missouri Network for Opiate Reform and Recovery. Drug Policy, Harm Reduction, and What s Next

Harm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD

Fraser Health Authority Supervised Consumption Site Evaluation Plan

Responding to BC s Overdose Epidemic

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

Carol Strike, PhD & Tara Marie Watson, PhD and the Working Group on Best Practice for Harm Reduction Programs in Canada

Harm Reduction In our communities, in our hospitals. AARM Conference September 14, 2017 Angela Baird RN, BN

Harms and harm reduction workbook. Country X

Harm Reduction at Lummi Tribal Health Center. Jessica Rienstra RN

HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications

Decriminalization of Personal Use of Psychoactive Substances

Decriminalization of Personal Use of Psychoactive Substances

Risk Behaviour and Prevention

Research on Supervised Injection Facilities: A Review of the Literature

Sistering A Woman s Place

ONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE. Dr. David Williams Chief Medical Officer of Health

Responding to B.C. s Illegal Drug Overdose Epidemic

References. Andresen, M. A., & Jozaghi, E. (2012). The point of diminishing returns: an examination of

Presented by: Carol Strike, PhD, Associate Professor at the Dalla Lana School of Public Health, University of Toronto.

Overview of drug-induced deaths in Europe - What does the data tell us?

IDU Outreach Project. Program Guidelines

Ministry of Health and Long-Term Care Overdose Prevention Sites: User Guide for Applicants

TEACH: Training practitioners in smoking cessation counselling

Minister s Opioid Emergency Response Commission Recommendations to the Minister Updated July 5, 2018

Evidence-based interventions for managing illicit drug dependence

VCH Overdose Surveillance Updates

REPORT ON EXPLORATORY SITE VISITS FOR COMPREHENSIVE USER ENGAGEMENT SITE (CUES)

Safeworks and Harm Reduction

Systematic Review Search Strategy

Ontario Harm Reduction Conference April 30 to May 2, 2017 Toronto, Ontario

The Business Case for Supervised Consumption in London, Ontario

Supportive Place for Observation and Treatment (SPOT): New Harm Reduction Programming at BHCHP

Preventing Harm from Substance Use: Harm Reduction. July 6, Dr. Murray Fyfe Medical Health Officer Vancouver Island Health Authority

Impaired driving statistics

Supervised Injection Facility Research Project

Prevalence and correlates of hepatitis C infection among users of North America s first medically supervised safer injection facility

Factors Associated with Syringe Sharing Among Users of a Medically Supervised Safer Injecting Facility

DRUG CHECKING DEMONSTRATION: INNOVATIVE HARM REDUCTION SERVICES IN ACTION

MEDIA BACKGROUNDER THE SALOME TRIAL ELIGIBLE PARTICIPANTS ROLE OF METHADONE

Drug Use, Harm Reduction, and HIP

Supervised Consumption Services. Operational Guidance

WHAT IS NO BUTTS ABOUT IT?

Technical Guidance Note for Global Fund HIV Proposals

Models of good practice in drug treatment in Europe. Project group

COUNTRY TABLE. MONTENEGRO.

Working Group on Best Practice for Harm Reduction Programs in Canada.

EMCDDA-update HIV/HCV among people who inject drugs: situation and response

The forgotten group: a new HIV outbreak amongst people who inject drugs. Patricia Anderson Lead CNS BBV Brownlee Centre

THAT in accordance with Section s.239 (2) (c) of the Municipal Act, 2001, Council convene in Closed Session to consider the following subject matter:

The Impact of the Opioid Crisis. Deborah A. McMahan, MD Health Commissioner Allen County Department of Health

Normalizing Conversation, Not Consumption

Infectious and Communicable Diseases Prevention and Control Program Annual Service Plan A. Community Need and Priorities We are situated rurally with

Healthy Pathways Forward Progress Report. May

THE INTERNATIONAL CANCER BENCHMARKING PARTNERSHIP: GLOBAL LEARNING FROM OUR RESULTS Harpal Kumar, Chief Executive, Cancer Research UK UICC World

Tackling Alberta s Opioid Crisis. November 22, 2017

Taking away the chaos The health needs of people who inject drugs in public places in Glasgow city centre

Responding to BC s Opioid Overdose Epidemic

Drug Surveillance Systems in Canada

Victorian Parliamentary Inquiry into the Drugs, Poisons and Controlled Substances Amendment (Pilot Medically Supervised Injecting Centre) Bill 2017

EVALUATION OF FASD PREVENTION AND FASD SUPPORT PROGRAMS. Philosophy/Theoretical Framework: Harm Reduction.

Should buprenorphine be covered for maintenance treatment in opioid dependent persons?

New trends in harm reduction in Europe: progress made challenges ahead

TITLE: Needle Exchange Programs in a Community Setting: A Review of the Clinical and Cost-Effectiveness

CARF s Consultative Approach to Long-term Care Accreditation. May 15, 2018

MANAGING DIFFICULT BEHAVIOURS IN THE

Historical Perspectives

Margot Kuo, Despina Tzemis, Ellison Richmond, Jane Buxton. CPHA 2012 June 12, 2012 Edmonton, AB

Re: Revisions to the Communicable Disease Control Manual, Chapter 3- Infection Control

Chronic Pain Management Services in Newfoundland and Labrador. Provincial Chronic Pain Management Working Group. Discussion Document

Reducing Harm or Producing Harm? Public Health Implications of Prosecuting HIV-positive People. Warren Michelow

Syringe Exchange Program Plan

Working with People Who Use Drugs in HIV Care Settings. August 29, 2017 Workshop C 2:00 3:30 p.m.

Alberta Alcohol and Drug Abuse Commission. POSITION ON ADDICTION AND MENTAL HEALTH February 2007

July 22, The Smoking Cessation Initiative Description- A Multi-Prong Approach: 1. RNAO Smoking Cessation (SC) Coordinators

City of Vancouver s Response to the Opioid Crisis Fire Chief Darrell Reid Vancouver Fire & Rescue Services (VF&RS)

Evidence Summary Title: Abstinence-plus HIV prevention programs in high-income countries: Evidence and implications for public health

2018 Training Opportunities

Limiting the spread of hepatitis C virus with Treatment as Prevention (TasP)

Rural Prevention and Treatment of Substance Abuse Toolkit

The Nova Scotia Take Home Naloxone Program. Amanda Hudson-Frigault, MA NS THN Coordinator

Transcription:

January 30 th, 2018 12:00 p.m. 1 p.m. (EDT) Supervised Injection Services: Evidence and Practice Mary Clare Kennedy, MA, PhD (cand) - University of British Columbia, BC Centre on Substance Use Tim Gauthier, MN-NP Insite Vancouver Welcome! The webinar will begin shortly! To hear audio for this event, please turn up your computer speakers. Please note this event will be recorded.

Coming up Mary Clare Kennedy MA, PhD (cand) University of British Columbia, BC Centre on Substance Use Tim Gauthier MN-NP Insite Vancouver

Current HIV/AIDS Reports. 2017; 14(5):161-183 Public health and public order outcomes associated with supervised drug consumption facilities: A systematic review Mary Clare Kennedy, Mohammad Karamouzian & Thomas Kerr

Background Supervised drug consumption facilities (SCFs) Supervised injection facilities (SIFs) Supervised inhalation rooms (SIRs)

Public health and public order objectives of SCFs 1) Reduce harms associated with illicit drug use A) Overdose-related morbidity & mortality B) Infectious disease transmission 2) Connect people who use drugs (PWUD) with addiction treatment and other health services 3) Reduce public order and safety problems associated with illicit drug use Hedrich et al., 2010

Where do SCFs exist? 90 in 7 countries in Europe 1 in Sydney, Australia 17 in Canada* BC: Vancouver (3), Surrey (2), Victoria (1), Kamloops (1), Kelowna (1) Ontario: Toronto (2), Ottawa (2) Quebec: Montreal (4) Alberta: Calgary (1) *11 Additional SCFs approved in Canada EMCDDA, 2017; Health Canada, 2018

Purpose of study 1) To systematically review existing quantitative research on the health and community impacts of SCFs. 2) To identify underexplored opportunities to inform future research specific to SCFs. Kennedy et al., Curr HIV/AIDS Rep. 2017

Methods: Search strategy Searched 6 databases: MEDLINE, EMBASE, Web of Science, PsychINFO, Google Scholar, CINAHL Reference lists, conference proceedings, key addiction journals Grey literature search (e.g., reports, dissertations) Kennedy et al., Curr HIV/AIDS Rep. 2017

Methods: PICOS framework for study inclusion Population: PWUD and broader communities in which SCFs are located Interventions: Use, establishment or operation of SCFs Comparison: No exposure to SCFs Outcomes: All individual- or population-level health or social outcomes Study design: Original quantitative studies that assessed associations between SCFs and outcome(s) for statistical or clinical significance Kennedy et al., Curr HIV/AIDS Rep. 2017

Methods: Exclusion criteria and quality assessment Excluded: review articles, case reports, commentaries, qualitative studies, descriptive studies, feasibility studies Quality assessment: National Heart, Blood and Lung Institute (NHBLI) Quality Assessment Tool for Observational Cohort and Cross-sectional studies NHBLI Quality Assessment Tool for Before-After (Pre-Post) Studies Joanna Briggs Institute s Critical Appraisal Checklist for Economic Evaluations Kennedy et al., Curr HIV/AIDS Rep. 2017

Results 47 eligible studies included (2003 2017) 28 from Vancouver 10 from Sydney, Australia 9 from European countries (Germany; Denmark; Spain; the Netherlands) Study designs: 17 prospective cohort 10 pre-post ecological 9 cross-sectional 8 mathematical simulation 3 series cross-sectional Kennedy et al., Curr HIV/AIDS Rep. 2017

Results Objective 1a: Reduce overdose (OD)- related morbidity and mortality 8 studies: 4/5 reduction in OD deaths 1/5 no association but low statistical power 1/1 reduction in OD emergency department presentations 1/1 reduction in OD ambulance attendances 1/1 no association with non-fatal OD Reduction in non-fatal overdose not key goal of SCFs 1/1 increased likelihood of OD within SCF likely due to greater exposure time at SCF Kennedy et al., Curr HIV/AIDS Rep. 2017

Results Objective 1b: Drug-related behaviours associated with infectious disease transmission and other harms 9 studies: 3/4 declines in syringe sharing 1/4 no association with syringe sharing but underpowered 2/2 declines in syringe reuse, outdoor injection, rushed injection 2/2 no association with injection-related infections 2/2 no changes in community drug use patterns (e.g., injection relapse/ cessation, binge drug use) Kennedy et al., Curr HIV/AIDS Rep. 2017

Results Objective 2: Connect PWUD w/addiction treatment & other services 13 studies: 4/5 increased uptake of addiction treatment 1/5 no association w/ inability to access treatment 6/6 increased use of other health and social services 1/1 drug checking more likely to reduce doses but not dispose of drugs 1/1 smoking cessation program smoking cessation care Kennedy et al., Curr HIV/AIDS Rep. 2017

Results Objective 3: Improve public order and safety 11 studies: 5/5 improved public order (i.e., reductions in public drug use, publiclydiscarded syringes/ litter) 6/6 no increases in crime (e.g., theft, robbery, drug dealing/ possession, incarceration rates) Kennedy et al., Curr HIV/AIDS Rep. 2017

Results Other health and social impacts 8 studies: 6/6 cost effective 5 of Insite ($200,000 - $6 million) 1 of unsanctioned, peer-run SCF 1/1 not associated with employment 1/1 increased consistent condom use among PWUD with regular but not casual partners Kennedy et al., Curr HIV/AIDS Rep. 2017

Discussion Reduce overdose-related harms Reduce risk of infectious disease transmission No impact on community drug use patterns Increased uptake of addiction treatment and other health and social services Improvements in public order & safety No impact on crime Cost effective Kennedy et al., Curr HIV/AIDS Rep. 2017

Discussion Directions for future research Long-term health impacts (e.g., sustained injection cessation) Innovations in SCF programming Assisted injection Supervised inhalation rooms Peer-run SCFs Women-only SCFs Mobile SCFs Integrated SCFs Kennedy et al., Curr HIV/AIDS Rep. 2017

Acknowledgements Participants of studies included in review Co-authors: Mohammad Karmouzian and Thomas Kerr BCCSU staff and administrative support: Deborah Graham, Tricia Collingham and the rest of the team Community groups and others who support this work Funders: Canadian Institutes of Health Research (CIHR), Social Sciences and Humanities Research Council (SSHRC), Mitacs Canada, Vanier Canada

Contact: mckennedy@alumni.ubc.ca

INSITE SUPERVISED INJECTION & NURSING PRACTICE Tim Gauthier, RN, BSN, MN RNAO January 30/18

HISTORY SUPERVISED INJECTION IN CANADA Insite opened in 2003 Response to Public Health Emergencies & public pressures 1990 s HIV & OD Deaths Research Program Exemptions granted yearly based on evidence Supreme Court of Canada upheld right to exemption while there is demonstrated need Civil Disobedience: VANDU, PHS, Dr Peter s, Nurses

#THEYTALKWEDIE

CURRENT CONTEXT SUPERVISED CONSUMPTION Public Health Crisis: Opioid Overdose Overdose Prevention Sites: volunteers, peers, harm reduction workers and nurses. Supervised Consumption Sites: varied models most include nurses Lack of clarity over what nurse do

LIGHTFOOT ET AL. (2009) CANADIAN NURSE JOURNAL

INSITE S PRIORITY PYRAMID OD & Inj. Emergencies HR ED Referrals Nursing Treatments

OVERDOSE AND INJECTION RELATED EMERGENCES Opioid OD Stimulant OD Other Toxicology Seizure Chest Pain Hypoglycemia Cotton Fever vs Sepsis Psychosis Arterial Injection

HARM REDUCTION EDUCATION Safer Injection Vein Care / Location Supplies and Equipment Infection Prevention Alternate Routes of Ingestion OD Prevention OD Response & THN Hygiene Opioid Replacement

NURSING IN THE IR

REFERRALS Primary Care Substance Use & Addictions Mental Health Dental Housing Food Income and Social Assistance Emergency & Acute Care Specialists

NURSING TREATMENTS PRIMARY NURSING CARE Wound Care POC HIV Testing STI Testing & Treatment Immunizations Primary Care Complaints Counselling & Management Plans Case Management Mental Health Crises & Suicidality Trauma & Emergency Management

BROADER ROLE CLARIFICATION RNAO / HRNA / CNA / COMMUNITY OF PRACTICE https://www.nursesforsis.com/uploads/2/5/3/6/25361002/nursing_pr actice_and_supervised_injection_final_draft.pdf

HARM REDUCTION NURSES ASSOCIATION The mission of HRNA is to recognize and foster advance harm reduction nursing through practice, education, research, and advocacy

CONTACT INFORMATION Please feel free to contact me with questions or comments about nursing practice and supervised injection Tim Gauthier Clinical Coordinator Insite & Onsite Tim.Gauthier@vch.ca Thank you!

35